Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus platinum-taxane induction therapy for locally advanced thymic carcinoma
ChiCTR2600133939Phase 2Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Sep 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in thymic carcinoma (TC), sponsored by Shanghai East Hospital. Primary endpoint: Objective response rate. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on ChiCTR2600133939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133939.